Xeris Biopharma Holdings Inc (STU:2B30)
€ 3.302 0.14 (4.43%) Market Cap: 490.65 Mil Enterprise Value: 684.05 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 70/100

Xeris Biopharma Holdings Inc at JPMorgan Healthcare Conference Transcript

Jan 11, 2024 / 08:00PM GMT
Release Date Price: €2.54 (+16.51%)
Bhavana Balakrishnan JPMorgan;Moderator

Good afternoon, everybody of you have to hope you had a great day for at the JPMorgan Health. I'm Bhavana Balakrishnan and associate here at the Healthcare Investment Banking team. Thank you so much for joining the presentation of the Xeris Biopharma. With us today, we have Paul Edick, who is the Chairman and Chief Executive Officer; and Allison Wey, SVP of IR and Corporate Communications. We'll leave time at the end for questions. But for now, over to you, Paul.

Paul Edick
Xeris Biopharma Holdings Inc - Chief Executive Officer, Director

Thank you. I appreciate it. And welcome. Good to see everybody today, and thank you to JPMorgan for having us. I'm going to go through our presentation today and we'll save some time for questions. We are a public company. Please pay attention to our forward-looking statements if you take a time to read that we appreciate it.

Xeris is an emerging biopharma company. We're a self-sustaining, growth-oriented business committed to making a difference to patients. I'm going

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot